Core Points - A class action lawsuit has been filed against Biohaven Ltd. in the U.S. District Court for the District of Connecticut on behalf of investors who acquired Biohaven securities during the period from March 24, 2023, to May 14, 2025 [1][3] - Investors have until September 12, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [1][3] Allegations - The lawsuit claims that Biohaven made false or misleading statements regarding the likelihood of regulatory approval for its drug troriluzole to treat SCA, as well as the strength of the supporting data [4] - Additionally, it is alleged that Biohaven overstated the effectiveness and clinical potential of BHV-7000 as a treatment for bipolar disorder [4]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Altimmune, Inc. following a significant decline in its stock price after the announcement of disappointing trial results for Pemvidutide [4][6][7] Group 1: Legal Investigation and Class Action - The firm is encouraging investors who suffered losses exceeding $75,000 in Altimmune between August 10, 2023, and June 25, 2025, to discuss their legal rights [1] - A federal securities class action has been filed against Altimmune, with a deadline of October 6, 2025, for investors to seek the role of lead plaintiff [4][8] - The lead plaintiff is defined as the investor with the largest financial interest who directs and oversees the litigation on behalf of the class [8] Group 2: Trial Results and Stock Performance - On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b MASH trial, which failed to achieve statistical significance in its primary endpoint of fibrosis reduction [6] - Following the announcement, Altimmune's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in one day [7]

Core Viewpoint - A securities class action lawsuit has been filed against Altimmune, Inc. for allegedly misleading investors regarding the results of its IMPACT Phase 2b MASH trial, leading to significant stock price decline [1][2][4]. Group 1: Allegations and Trial Results - The lawsuit claims that Altimmune executives provided overly positive statements while concealing adverse facts about the trial results [2]. - The press release announcing the trial results was titled positively, despite one of the primary endpoints not achieving statistical significance [2][3]. - The trial showed a positive trend in fibrosis improvement, but the statistical significance was not met due to a higher-than-expected placebo response [3]. Group 2: Market Reaction - Following the announcement of the trial results, Altimmune's stock price fell from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in one day [4]. Group 3: Legal Proceedings - Investors who purchased shares of Altimmune during the class period are encouraged to contact the law firm representing the class action before the lead plaintiff motion deadline on October 6, 2025 [5].

Core Viewpoint - XPLR Infrastructure, LP is facing a federal securities class action lawsuit due to significant operational changes and alleged misleading statements regarding its business model and financial practices [1][4]. Group 1: Company Actions and Changes - On January 28, 2025, XPLR announced the suspension of cash distributions to common unitholders and a shift from its yieldco model to a new strategy focused on utilizing retained operating cash flows for investments [3]. - The announcement led to a decline in the price of XPLR's common units by $5.31, approximately 33.6%, from $15.80 on January 27, 2025, to $10.49 on January 29, 2025 [3]. Group 2: Allegations in the Lawsuit - The lawsuit claims that XPLR made materially false and/or misleading statements regarding its operational struggles as a yieldco, financing arrangements, and plans to halt cash distributions while redirecting funds to resolve financing issues [4].

NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Lineage, Inc. (“Lineage” or the “Company”) (NASDAQ: LINE) in, or traceable to, the registration statement issued in connection with the Company’s July 2024 initial public offering (the “IPO”). For more information, submit a form at Lineage, Inc. Shareholder Class Action Lawsuit, email Inv ...

Core Viewpoint - A class action lawsuit has been filed against Vestis Corporation for allegedly providing misleading statements about its business growth and performance during the class period from May 2, 2024, to May 6, 2025 [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased or acquired Vestis securities during the specified class period [1]. - Investors have until August 8, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [1]. Group 2: Allegations Against Vestis - The complaint alleges that Vestis made overwhelmingly positive statements while concealing material adverse facts about its business growth capabilities [3]. - Specifically, it is claimed that Vestis would be unable to execute planned strategic initiatives aimed at improving customer experience and driving new customer growth [3]. Group 3: Financial Performance - On May 7, 2025, Vestis announced disappointing financial results for Q2 of fiscal 2025, withdrawing its revenue and growth guidance for the full fiscal year [4]. - The company attributed its poor performance to "lost business in excess of new business" and "lower adds over stops," indicating a decline in volume changes with existing customers [4]. - Following this announcement, Vestis' stock price plummeted from $8.71 per share on May 6, 2025, to $5.44 per share on May 7, 2025, marking a decline of approximately 37.54% in one day [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of RxSight, Inc. during the specified Class Period of their potential entitlement to compensation through a class action lawsuit [1][4]. Group 1: Class Action Details - The Class Period for the RxSight securities is from November 7, 2024, to July 8, 2025, and the lead plaintiff deadline is September 22, 2025 [1][2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5]. - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions [3]. Group 2: Allegations Against RxSight - The lawsuit alleges that RxSight made false and misleading statements regarding its business performance, including issues with product adoption and overstated demand [4]. - It is claimed that RxSight was unlikely to meet its previously issued financial guidance for fiscal year 2025 due to these issues [4]. - The misleading statements led to investor damages when the true situation was revealed [4].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Petco To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Petco between January 14, 2021 and June 5, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, July 30, 2025 (GLOBE NEWSWIR ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Petco Health and Wellness Company, Inc. securities between January 14, 2021, and June 5, 2025, of the upcoming lead plaintiff deadline on August 29, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Petco securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by August 29, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that Petco made false and misleading statements regarding the sustainability of its pandemic-related business model and the strength of its product strategy [5]. - It is claimed that the defendants downplayed the severity of issues affecting Petco's business and overstated its ability to achieve sustainable, profitable growth [5]. - The lawsuit asserts that when the true details were revealed, investors suffered damages due to the misleading public statements made by the defendants [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against RxSight, Inc. due to allegations of misleading statements and failure to disclose significant operational challenges that have negatively impacted the company's financial performance [2][4]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses exceeding $75,000 in RxSight between November 7, 2024, and July 8, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against RxSight, with a deadline of September 22, 2025, for investors to seek the role of lead plaintiff [2][6]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Allegations Against RxSight - The complaint alleges that RxSight and its executives violated federal securities laws by making false and misleading statements regarding the company's sales and product demand [4]. - Specific issues cited include "adoption challenges" leading to declines in sales and utilization, overstated demand for products, and an inability to meet previously issued financial guidance for fiscal year 2025 [4]. - Following the release of preliminary second quarter 2025 financial results, RxSight's stock price fell by $4.84, or 37.8%, closing at $7.95 per share on July 9, 2025, due to significant declines in sales and lowered revenue guidance [5].